Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Feasibility × Trastuzumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 27 Neoplasms 4 Cardiotoxicity 4 Stomach Neoplasms 3 Neurotoxicity Syndromes 1 Neoplasms, Second Primary 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 HER2-positive Breast Cancer 1 HER2+ Breast Cancer 1 Feasibility 1 Fatigue 1 Breast Cancer Organoids 1 Brain Neoplasms 1

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡